Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.36 |
| ▸ | IDO1 | P14902 | 6/20 | 0.35 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 3/20 | 0.33 |
| ▸ | HTR2B | P41595 | 3/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13499161 | 0.97 | KDM1A (0.36) | KDM1AIDO1KDM1BBACE1HTR2B | |
| SCHEMBL3323591 | 0.82 | TRPV1 (0.43) | KDM1AKDM1B | |
| SCHEMBL618100 | 0.82 | TRPV1 (0.43) | KDM1AKDM1B | |
| SCHEMBL18200245 | 0.82 | IDO1 (0.37) | IDO1HTR2BLMNA | |
| SCHEMBL619899 | 0.82 | KDM4E (0.41) | LMNA | |
| SCHEMBL3322340 | 0.82 | TRPV1 (0.43) | KDM1AKDM1B | |
| SCHEMBL3804677 | 0.82 | TRPV3 (0.38) | KDM1AHTR2BAHROPRD1LMNA | |
| SCHEMBL619444 | 0.82 | HDAC3 (0.39) | IDO1LMNA | |
| SCHEMBL3794807 | 0.82 | TRPV3 (0.38) | KDM1AHTR2BAHROPRD1LMNA | |
| SCHEMBL618002 | 0.82 | TRPV3 (0.38) | KDM1AHTR2BAHROPRD1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931681-B1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS SA (CH) | 2012-11-14 | — | — | EP | disclosed |
| US-20120277259-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-11-01 | — | — | US | disclosed |
| US-20120041011-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-02-16 | — | — | US | disclosed |
| US-20110021549-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-01-27 | — | — | US | disclosed |
| US-7842703-B2 | Substituted benzofused derivatives and their use as vanilloid receptor ligands | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-11-30 | — | — | US | disclosed |
| US-20080269253-A1 | Substituted Benzofused Derivatives and Their Use as Vanilloid Receptor Ligands | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2008-10-30 | — | — | US | disclosed |
| EP-1931681-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | Glenmark Pharmaceuticals S.A. (CH) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007042906-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269253-A1 | Substituted Benzofused Derivatives and Their Use as Vanilloid Receptor Ligands | TRPV1, GPR17, TRPV6 | KDM1A 3486/4885IDO1 3716/4885KDM1B 3087/4885 |
| US-20120041011-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | TRPV1, GPR17, TRPV6 | KDM1A 3391/4885IDO1 3741/4885KDM1B 3041/4885 |
| US-20110021549-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | TRPV1, GPR17, TRPV6 | KDM1A 3391/4885IDO1 3741/4885KDM1B 3041/4885 |
| US-20120277259-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | TRPV1, GPR17, TRPV6 | KDM1A 3486/4885IDO1 3716/4885KDM1B 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.